Samsung Biologics to Showcase Global Expansion and Strategic Initiatives at DCAT Week 2026
ByAinvest
Tuesday, Mar 24, 2026 7:44 pm ET1min read
LLY--
Samsung Biologics is showcasing its global expansion and strategic initiatives at DCAT Week 2026 in New York City. The company's Executive Vice President and Head of Sales and Operations, Kevin Sharp, presented updates on capacity and geographical expansion, highlighting ongoing investments and key collaborations, including a partnership with CEPI and an open innovation center with Eli Lilly. Throughout the week, Samsung Biologics' leadership will engage with clients to discuss manufacturing and development capabilities.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet